Abstracts tagged "axial spondyloarthritis"

Abstract Number: 2076 • 2018 ACR/ARHP Annual Meeting
Transmembrane TNF (tmTNF) Transgenic Mice Exhibit Enlarged Lymph Nodes and Elevated Numbers of High Endothelial Cells Associated with Increased Lymphocyte Recruitment
Kim Jeucken¹, Jan Piet van Hamburg², Merlijn Kaaij³, Leonie van Duivenvoorde³, Dominique Baeten³ and Sander W. Tas², ¹2Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology & immunology Center | Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology and Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The NF-κB family of transcription factors plays a crucial role in chronic inflammatory diseases and can be activated via two distinct pathways. Non-canonical NF-κB…
Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Daeria O. Lawson^1,2, Maria Eraso³, Lawrence Mbuagbaw⁴, Theresa Aves⁵, Alvin Leenus⁴, Marianinha Joanes⁶, Ahmed Omar^1,7 and Robert D Inman^8,9, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ⁵St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Boston University School of Medicine, Boston, MA, United States, Boston, MA, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 893 • 2018 ACR/ARHP Annual Meeting
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
Rebecca S. Overbury¹, Shaobo Pei², Gopi Penmetsa², Grant W. Cannon², Daniel O. Clegg³, Brian Sauer⁴ and Jessica Walsh⁵, ¹Internal Medicine, Divison of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT
Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 1024 • 2018 ACR/ARHP Annual Meeting
Unique Pattern of Lectin Pathway Complement Protein Levels in Axial Spondyloarthritis
Anne Troldborg^1,2,3, Steffen Thiel¹, Clara Mistegaard Joergensen⁴, Kristian Stengaard-Pedersen^3,5 and Anne Gitte Loft^3,6, ¹Biomedicine, Aarhus University, Aarhus, Denmark, ²clinical medicine, Aarhus University, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Emergency Medicine, Regional Hospital Horsens, Horsens, Denmark, ⁵Clinical medicine, Aarhus University, Aarhus, Denmark, ⁶Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: Spondyloarthritis (SpA) represents a group of immune-mediated inflammatory diseases that exhibit overlapping clinical features, genetic predisposition and a not fully understood pathogenesis. Inflammation and…
Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Robert B.M. Landewé¹, Désirée van der Heijde², Maxime Dougados³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Bengt Hoepken⁶, Karen Thomas⁶ and Lianne S. Gensler⁷, ¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, ⁴Ruhr-University Bochum, Herne, Germany, ⁵Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷University of California, San Francisco, CA
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…
Abstract Number: 1616 • 2018 ACR/ARHP Annual Meeting
Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study
Denis Poddubnyy¹, Robert D Inman², Joachim Sieper¹, Fabiana Ganz³ and Maja Hojnik⁴, ¹Charité Universitätsmeidzin Berlin, Berlin, Germany, ²Department of Medicine, University of Toronto, Toronto, ON, Canada, ³AbbVie, Baar, Switzerland, ⁴AbbVie, Ljubljana, Slovenia
Background/Purpose: There is limited evidence on the phenotypic characteristics of axial spondyloarthritis (axSpA) patients (pts) in various geographic regions around the world. This analysis aimed…
Abstract Number: 2569 • 2018 ACR/ARHP Annual Meeting
Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab
Philip J. Mease¹, Filip van Den Bosch², Uta Kiltz³, Patrick Zueger⁴, Kun Chen⁴, Meijing Wu⁴ and Jaclyn K. Anderson⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Ghent University, Ghent, Belgium, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis, a key pathology in non-radiographic axial spondyloarthritis (nr-axSpA), has been difficult to treat with conventional therapies and may take longer to resolve than…
Abstract Number: 1620 • 2018 ACR/ARHP Annual Meeting
Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy
Gillian Fitzgerald^1,2, Jason Wyse³, Tochukwu Anachebe⁴, Ronan Mullan⁵, David Kane⁶, Kevin McCarroll⁷ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³School of Computer Science and Statistics, Trinity College Dublin, Dublin 2, Ireland, ⁴Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁵Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁶Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, ⁷Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: The severe consequences of osteoporosis in the general population are well outlined. In axial spondyloarthropathy (axSpA), osteoproliferation of the spine means posterioanterior (PA) dual-energy…
Abstract Number: 2581 • 2018 ACR/ARHP Annual Meeting
Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Theresa Hunter¹, David Sandoval Calderon¹, Steve Lobosco², Rachel Moon², Gary Milligan³ and Rebecca Bolce¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Adelphi Real World, Macclesfield, United Kingdom, ³Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: To compare TNF inhibitor (TNFi) use and switching patterns among patients with nr-axSpA in the United States (US) and Europe (EU). Methods: Data from…
Abstract Number: 330 • 2018 ACR/ARHP Annual Meeting
The IMPACT of a Referral Algorithm for Axial Spondyloarthritis: Four Month Follow-up in Patient Reported Outcomes
Maha Jamal¹, Amber Korver², Martijn Kuijper³, Deirisa Lopes Barreto¹, Frank van den Hoogen⁴, Cathelijne W. Y. Appels⁵, Anneke Spoorenberg⁶, Bart Koes⁷, Lonneke van Hoeven⁸, JMW Hazes⁹ and Angelique EAM Weel³, ¹Maasstad Hospital, Rotterdam, Netherlands, ²Erasmuc Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Radboud Medical center, Nijmegen, Netherlands, ⁵Rheumatology, Amphia Hospital, Breda, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Erasmuc Medical center, Rotterdam, Netherlands, ⁸Erasmus Medical center, Rotterdam, Netherlands, ⁹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: A substantial amount of patients with chronic low back pain (CLBP) have axial spondyloarthritis (axSpA), but early recognition of these patients is difficult for…
Abstract Number: 1621 • 2018 ACR/ARHP Annual Meeting
Higher Serum Uric Acid Levels Protect Against Osteoporosis in Patients with Axial Spondyloarthropathy
Gillian Fitzgerald^1,2, Tochukwu Anachebe³, Ronan Mullan⁴, David Kane⁵, Kevin McCarroll⁶ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁴Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁵Department of Rheumatology, Tallaght Hospital, Dublin 24, Ireland, ⁶Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: High serum urate (SUA) is a risk factor for metabolic disease, including hypertension and coronary artery disease. However, SUA has an antioxidant effect and…
Abstract Number: 2601 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
Hong-Ki Min¹, Hyonjoung Cho² and Sung-Hwan Park³, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Armed Forces Capital hospital, Armed Forces Medical Command, Seongnam, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The purpose of the present study was to examine the therapeutic effect of NSAIDs on active inflammatory lesions (bone marrow oedema [BMO]) in the…
Abstract Number: 642 • 2018 ACR/ARHP Annual Meeting
Cost of Illness Analysis before and after Initiation of Tumour Necrosis Factor α Inhibitors in Patients with Axial Spondyloarthritis
Imke Redeker¹, Falk Hoffmann², Johanna Callhoff¹, Hildrun Haibel³, Joachim Sieper⁴, Angela Zink⁵ and Denis Poddubnyy⁴, ¹Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany, ²Department of Health Services Research, Carl von Ossietzky University, Oldenburg, Germany, ³Charité Universitätmedizin Berlin, Berlin, Germany, ⁴Rheumatology, Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: Tumour necrosis factor-α inhibitors (TNFi) are an effective but rather expensive treatment option in axial spondyloarthritis (axSpA) patients who fail conventional treatment. The aim…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].